CALL OPTION AMENDMENT AGREEMENT dated as of April 6, 2020 Between LIGAND PHARMACEUTICALS INCORPORATED and GOLDMAN SACHS & CO. LLCCall Option Amendment Agreement • May 8th, 2020 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CALL OPTION AMENDMENT AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of April 6, 2020 between Ligand Pharmaceuticals Incorporated (“Company”) and Goldman Sachs & Co. LLC (“Dealer”).
CALL OPTION AMENDMENT AGREEMENT dated as of April 6, 2020 Between LIGAND PHARMACEUTICALS INCORPORATED and DEUTSCHE BANK AG, LONDON BRANCHCall Option Amendment Agreement • May 8th, 2020 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CALL OPTION AMENDMENT AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of April 6, 2020 between Ligand Pharmaceuticals Incorporated (“Company”) and Deutsche Bank AG, London Branch (“Dealer”).
CALL OPTION AMENDMENT AGREEMENT dated as of April 6, 2020 Between LIGAND PHARMACEUTICALS INCORPORATED and BARCLAYS BANK PLCCall Option Amendment Agreement • May 8th, 2020 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CALL OPTION AMENDMENT AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of April 6, 2020 between Ligand Pharmaceuticals Incorporated (“Company”) and Barclays Bank PLC (“Dealer”).
Asset Purchase Agreement by and between ICAGEN, INC. CERTAIN SUBSIDIARIES OF ICAGEN INC. and ADJACENT ACQUISITION CO., LLC FEBRUARY 11, 2020Asset Purchase Agreement • May 8th, 2020 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
